Hidradenitis Suppurativa: A Systematic Review and Meta-analysis of Therapeutic Interventions

• Published in: Indian journal of dermatology, venereology, and leprology venereology, and leprology, 2019-05, Vol.85 (3), p.248-257
• Main Authors: Tchero, Huidi, Herlin, Christian, Bekara, Farid, Fluieraru, Sergiu, Teot, Luc
• Format: Article
• Language: English
• Subjects: Acne; Adalimumab; Algorithms; Anakinra; Anti-Bacterial Agents - administration & dosage; Antibiotics; Cancer therapies; Care and treatment; Clinical trials; Combined Modality Therapy - methods; Dermatology; Diagnosis; Disease; Evidence-based medicine; Hidradenitis Suppurativa - diagnosis; Hidradenitis Suppurativa - immunology; Hidradenitis Suppurativa - therapy; Human health and pathology; Humans; Immunosuppressive Agents - administration & dosage; Immunotherapy; Laser Therapy - methods; Life Sciences; Meta-analysis; Metronidazole; Monoclonal antibodies; Pain; Quality; Randomized Controlled Trials as Topic - methods; Retinoids - administration & dosage; Skin; Skin diseases; Systematic review; Tetracyclines; Therapeutics; TNF inhibitors; Tumor necrosis factor-TNF
• ISSN: 0378-6323; 0973-3922; 1998-3611
• DOI: 10.4103/ijdvl.IJDVL_69_18

Hidradenitis suppurativa is a chronic inflammatory condition that affects skin regions bearing apocrine glands. Although hidradenitis suppurativa is difficult to treat and cure, the currently available treatments are directed toward managing the lesions and associated symptoms. This review presents an evidence-based outline of the available treatment options. We searched four electronic databases and extracted data from retrieved studies for qualitative or quantitative analysis. Meta-analysis was conducted using the comprehensive meta-analysis software to generate pooled standardized mean differences or risk ratios. Numerous medical treatments are available for hidradenitis suppurativa such as antibiotics, retinoids, antiandrogens, immunosuppressive and anti-inflammatory agents and radiotherapy for early lesions. Adalimumab, an anti-tumor necrosis factor antibody, was superior to placebo in reducing Sartorius score (standardized mean difference = −0.32, confidence interval [−0.46, −0.18], P < 0.0001) and pain (risk ratio = 1.42, confidence interval [1.07, 1.9], P = 0.02), when given weekly (not every other week). Combination therapies (such as antibiotics and hyperbaric oxygen therapy) have been tested, which have shown promising results that are yet to be confirmed. Based on the quality of evidence, the most recommended treatments for hidradenitis suppurativa include adalimumab and laser therapy. Surgery (either by simple excision or complete local excision followed by skin graft) is the first choice for intractable disease presenting in the late stages. However, the evidence on most of these treatments is deficient and further randomized trials are needed to establish the most efficient therapies for hidradenitis suppurativa management.